x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Sep 26, 2016 7:50 EST

Cellgen Diagnostics: Extending cancer patients lives by making sure the right person, takes the right drug, at the right time.

iCrowdNewswire - Sep 26, 2016

Cellgen Diagnostics

Cellgen Diagnostics

Extending cancer patients lives by making sure the right person, takes the right drug, at the right time.

COMPANY OVERVIEW

Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.

INDUSTRY OVERVIEW

Today’s healthcare system is in a crisis and it is largely due to the one size fits all treatment for late stage diseases. The top ten highest-grossing drugs in the United States helps as low as 1 in 25 of the people who take them. In 2011, it is estimated that over $350B was wasted in US healthcare. But there is an answer…Precision Medicine.

Precision Medicine is when the right person takes the right drug at the right time. However, Precision Medicine only happens when a diagnostic test is paired with a therapeutic to ensure the patient’s genetic profile is a match for the particular drug. This pairing is called a Companion Diagnostic.Companion Diagnostics enable Precision Medicine, so in the future, you will not speak of one without the other.

Precision Medicine is transforming Cancer Care and is at It’s Tipping Point

  • 42 percent of all drugs in the pipeline have a companion diagnostic
  • Oncology leads the way with 73 percent of the pipeline represented by precision medicine
  • Entire Precision Medicine Ecosystem Benefits: Patients, Payers, Physicians, Pharma Cos

 

Precision Medicine and Companion Diagnostics are the driving forces behind eradicating cancer and will serve as a major catalyst in reducing the cost of healthcare in America.

TECHNOLOGY

Running on Cellgen’s proprietary platform, each disposable test will yield inclusion / exclusion data, while also leveraging proprietary machine learning algorithms to deliver intelligent, quantitative and actionable results to oncologists in under 5 hours as opposed to the current standard of 10-14 days. This information will help inform patients, physicians, oncologists, and others on how best to simplify and optimize life-saving clinical protocols.

Designed to detect DNA, RNA, and Proteins, Cellgen’s platform features a proprietary on-chip enrichment and detection workflow perfectly suited to be installed as the premier Companion Diagnostic testing system within leading oncology clinics globally.

IMMENSE MARKET OPPORTUNITY FOR COMPANION DIAGNOSTICS

The global companion diagnostics market is expected to grow at a 22.7% CAGR reaching $8.7 billion by 2019. Advancing molecular technologies, the encouragement/requirement by the FDA for companion diagnostics and the increasing costs of traditional drug discovery will continue to increase the adoption of companion diagnostics.

BUSINESS MODEL

Cellgen will initially adopt a “Companion Similar” Market Strategy. We will target (or duplicate) established companion diagnostic tests which are already on the market and present a significant market opportunity. This strategy De-risks the venture by removing lengthy and expensive biology clinical trials. We will actively validate proven Biomarkers on the Cellgen platform. Our less invasive, less expensive and much faster platform will be welcomed by the marketplace.

 

COMPANY SLIDESHARE

WHAT KEY OPINION LEADERS ARE SAYING…

“ONCOLOGY IS ON FIRE WITH [PERSONALIZED MEDICINE], WITH TREATMENT SELECTIONS BASED ON INDIVIDUAL MOLECULAR CHARACTERISTICS. THIS IS ALSO HAPPENING WITH CHRONIC INFECTIOUS DISEASES, AND GENETIC DISEASES ARE NOT FAR BEHIND”

—Janet Woodcock, Director

Center for Drug Evaluation and Research,

U.S. Food and Drug Administration

TRACTION

Negotiating license with Lawrence Livermore Labs to acquire 4 patents and 1000+ validated infectious disease probes for our platform.

JUNE, 2016

Exclusively licensed a novel electrochemical platform to monitor the response of immunotherapy from Oakland University.

MAY, 2016

Signed Partnership Agreement with University of Portsmouth in the UK to jointly work on the development of Immunotherapy assays.

MAY, 2016

Signed Option agreement to Acquire Machine Learning Algorithms from Rockefeller University

APRIL, 2016

Developed Automated Robot to perform in house Lab-Developed-Tests (LDTs)

FEBRUARY, 2016

Collaborated with Johns Hopkins University on the Development of a panel of diagnostic tests.

JUNE, 2015

Transferred Tech to Corporate Lab

MAY, 2015

Opened Corporate lab

APRIL, 2015

Licensed Technology from UCSD

OCTOBER, 2012

TESTIMONIALS

Cellgen’s ability to measure gene expression rapidly and without PCR bias will be a game changer for both basic research and clinical labs. I’m excited to become a BETA tester and an early adopter of the technology. I’m sure my colleagues will do the same upon commercialization
Tony De Tomaso, Ph.DAssociate Professor of Molecular and Cellular
Tony De Tomaso, Ph.D

LEADERSHIP

Lavance L Northington

Lavance L Northington

Executive Officer

 
Brings more than 25 years of start-up and corporate leadership experience. 25x return upon exit with most recent venture.
Gary Gust

Gary Gust

Technology Officer

 
Gary has designed and developed more than a dozen FDA approved clinical laboratory automation instruments, including Genmark’s XT-8 DNA detection platform
Sylvia Norman

Sylvia Norman

Scientific Officer

 
11 issued patents and 25+ yrs, Sylvia has designed, developed and validated diagnostic assays for industry leaders like Gen-Probe, DermTech, Nanogen, Strategene

 

 
Contact Information:

Lavance L Northington

View Related News >
support